Core Viewpoint - The company reported a revenue increase of 22.25% year-on-year for the first three quarters of 2025, indicating strong growth in its financial performance [1] Financial Performance - The company's operating revenue for the first three quarters reached 267 million yuan [1] - Net profit attributable to shareholders was 76.232 million yuan, reflecting a year-on-year growth of 7.08% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 67.078 million yuan, with a year-on-year increase of 9.79% [1] - Basic earnings per share stood at 0.29 yuan [1]

Group 1 - The company, Keta Bio, announced on October 21 that its 15th meeting of the third board of directors was held via communication voting on October 20, 2025 [1] - The meeting reviewed documents including the proposal for the third quarter report of 2025 [1] Group 2 - The article highlights the need to shift funding focus from excessive investment in housing and infrastructure to enhancing investment in the livelihood sector [1]

证券代码：300858 证券简称：科拓生物 公告编号：2025-044 北京科拓恒通生物技术股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京科拓恒通生物技术股份有限公司（以下简称"公司"或"科拓生物"） 及全资子公司内蒙古科拓生物有限公司（以下简称"内蒙科拓"）于近期收到国 家知识产权局颁发的 3 项专利证书，具体情况如下： | 序号 | 发明名称 | 专利号 | 专利权人 | 专利 类型 | 申请日期 | 授权日期 | 证书号 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一种用于预防和/或治 疗糖尿病性视网膜病 变和保护视力的鼠李 糖乳酪杆菌及其后生 | ZL202410 843371.X | 科拓生物 | 发明专 利 | 2024-6-27 | 2025-10-3 | 第 8331799 | 号 | | | 元制品和应用 干酪乳杆菌 在 Zhang | | | | | | | | | 2 | 制备治疗皮肤病的制 | ZL20 ...

Group 1 - The core viewpoint of the article highlights the financial performance of Keta Bio, reporting a revenue of approximately 267 million yuan for the first three quarters of 2025, representing a year-on-year increase of 22.25% [1] - The net profit attributable to shareholders of the listed company is approximately 76.23 million yuan, reflecting a year-on-year increase of 7.08% [1] - The basic earnings per share is reported at 0.29 yuan, which is a year-on-year increase of 7.41% [1]

证券代码：300858 证券简称：科拓生物 公告编号：2025-042 2、本次会议于 2025 年 10 月 20 日以通讯表决方式进行。 3、本次会议应出席董事 7 人，实际出席董事 7 人。 4、本次董事会由董事长孙天松女士召集和主持，公司高级管理人员列席了 本次董事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《北京科拓恒通生物技术股份有限公司章程》的有关规定，会议合法、 有效。 二、董事会会议审议情况 北京科拓恒通生物技术股份有限公司 第三届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、北京科拓恒通生物技术股份有限公司（以下简称"公司"）第三届董事会 第十五次会议通知于 2025 年 10 月 17 日以邮件通知方式向各位董事发出，同时 列明了会议的召开时间、内容和方式。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 三、备查文件 1、《北京科拓恒通生物技术股份有限公司第三届董事会第十五次会议决议》； 2、《北京科拓恒通生物技术股份有限公司第三届董事 ...

北京科拓恒通生物技术股份有限公司 2025 年第三季度报告 证券代码：300858 证券简称：科拓生物 公告编号：2025-043 北京科拓恒通生物技术股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： □是 否 1 北京科拓恒通生物技术股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 104,043,568.35 | 28.98% | 267,389,193.46 | 22.25% | | 归属于上市公司股东 | 35,026,934.69 | 26.56% | 76,231,997.73 | 7.08% | | 的净利润（元） | | | | | | 归属于上市公司股东 的扣除非经常性损益 | 31, ...

Group 1 - Harbin Air Conditioning plans to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. The subsidiary reported a net profit of -16.0963 million yuan for 2024, which is 218.83% of the previous year's net profit absolute value [1] - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 45% to 65% [1][2] - Gansu Energy anticipates a net profit of 1.55 billion to 1.6 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 11.86% to 15.47% [2][3] Group 2 - Dongfang Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 60.83% to 93% [4] - Meili Eco announced that its subsidiary won a bid for an EPC project worth 2.375 billion yuan [6] - Bohai Chemical's wholly-owned subsidiary will undergo routine maintenance for its 600,000 tons/year PDH unit, expected to last about 30 days [8] Group 3 - Qin Port Co. reported a total throughput of 317.02 million tons for the first nine months of 2025, a year-on-year increase of 5.56% [10] - Jianglong Shipbuilding won a bid for a 72.99 million yuan fishery enforcement vessel project, accounting for 4.22% of its 2024 audited revenue [11] - Longyuan Technology expects a net profit of 35 million to 40 million yuan for the first three quarters of 2025, representing a year-on-year increase of 50.11% to 71.55% [12] Group 4 - Naipu Mining anticipates a net profit of 61 million to 66 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 45.16% to 49.32% [14] - Jinggong Steel Structure reported a cumulative contract amount of 17.98 billion yuan for the first nine months of 2025, a year-on-year increase of 4.8% [15][16] - Shenzhen Gas reported a net profit of 918 million yuan for the first three quarters of 2025, a year-on-year decrease of 13.08% [17] Group 5 - Yabao Pharmaceutical's subsidiary received a drug registration certificate for a new diabetes medication [18] - Shaanxi Coal's coal production in September was 14.56 million tons, a year-on-year increase of 5.34% [20] - Sifang New Materials reported a 15.94% year-on-year decline in concrete production for the first three quarters [22] Group 6 - Nanjing Foods reported a consolidated revenue of 276 million yuan in September, a slight increase of 0.0016% year-on-year [23] - Pulaike received a new veterinary drug registration certificate for a flea and tick treatment [24] - Zhucheng Technology received a cash dividend of 15 million yuan from its subsidiary [25] Group 7 - David Medical's subsidiary received a medical device registration certificate for a portable electronic endoscope image processor [26] - Zhongtong Bus reported a 36.88% year-on-year increase in sales in September, totaling 1,106 units [27] - Xiantan Co. reported a 11.95% year-on-year increase in chicken sales revenue in September [28] Group 8 - Bojun Technology expects a net profit of 552 million to 662 million yuan for the first three quarters of 2025, a year-on-year increase of 50% to 80% [30] - Haishi Pharmaceutical's innovative pain relief drug clinical trial application has been accepted [31] - Lingxiao Pump Industry used 80 million yuan of idle funds to purchase financial products [32] Group 9 - Qiangda Circuit's subsidiary completed business registration changes to expand its operational scope [33] - *ST Tianyu's controlling shareholder applied for bankruptcy liquidation due to severe financial difficulties [34] - Baolidi's shareholder plans to reduce holdings by up to 1 million shares [36] Group 10 - Zijin Mining completed the acquisition of Kazakhstan's Raygorodok gold mine, controlling 100% of its rights [44] - Zhonggang Luoyang's indirect controlling shareholder completed a capital increase, raising registered capital from approximately 26.666 billion yuan to 44.824 billion yuan [46] - Jinyu Jidong's director resigned due to work adjustments [47]

Core Insights - On October 12, no A-share listed companies disclosed any increase in shareholding, while six companies reported share reductions [1] Group 1: Companies Reporting Share Reductions - Lian Ce Technology's controlling shareholder's concerted actors plan to reduce their holdings by no more than 2.98% [2] - Baolidi's shareholder holding over 5% (Yunnan Trust) plans to reduce holdings by no more than 1 million shares [2] - Zhongrong Electric's controlling shareholder's concerted actors intend to reduce their holdings by no more than 0.999% [2] - Ketaobiological's specific shareholder Zhang Liebing plans to reduce holdings by no more than 1.8976% [2] - Yirui Biological's controlling shareholder and its concerted actors plan to reduce holdings by no more than 3% [2] - Shanghai Hohong's major shareholder Xinggang Rongchuang plans to reduce holdings by no more than 1% [2]

科拓生物（300858）(300858.SZ)发布公告，持有股4.1764%的特定股东张列兵计划在次减持公告披露之 日起3个交易日后的3个月内(即2025年10月16日至2026年1月15日)以集中竞价、大宗交易的方式拟减持 公司股份数量不超过500万股，即不超过公司股份总数的1.8976%。 ...

Group 1 - The core point of the article is that Zhang Liebing, a specific shareholder holding 4.1764% of Keta Bio (300858.SZ), plans to reduce his shareholding [1] - The planned reduction will occur within three months starting from October 16, 2025, to January 15, 2026 [1] - The maximum number of shares to be reduced is 5 million, which accounts for no more than 1.8976% of the company's total shares [1]